Skip to main content
Log in

Pegaspargase preferred option in acute lymphoblastic leukaemia

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Notes

  1. The study was sponsored by Baxalta, a member of the Takeda group of companies.

Reference

  • Hu X, et al. The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis. Health Economics Review : 29 Dec 2019. Available from: URL: https://doi.org/10.1186/s13561-019-0257-3

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pegaspargase preferred option in acute lymphoblastic leukaemia. PharmacoEcon Outcomes News 844, 30 (2020). https://doi.org/10.1007/s40274-020-6493-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-6493-2

Navigation